Bausch + Lomb's LuxLife IOL receives CE mark approval in Europe

News
Article

The LuxLife full range of vision IOL is available in a range of cylinders spanning from +0.75D to +6.00D.

Graphic of CE Marks Image credit: AdobeStock/AndreasPrott

Bausch + Lomb is expecting LuxLife IOLs to be commercially available in Europe in the coming weeks, with a toric version of the lens to follow. Image credit: AdobeStock/AndreasPrott

Bausch + Lomb has announced CE mark approval for its LuxLife full range of vision (IOL).1 The preloaded, non-diffractive IOL utilizes Pure Refractive Optics (PRO) technology in order to provide continuous vision for the entire optical diameter and from distance to near, according to a news release.

The company stated in the release that the announcement “reinforces Bausch + Lomb’s commitment to equip cataract surgeons with choices to fit the right lens to the right patient following the recent launches of enVista Envy full range of vision lenses in the United States and Canada and enVista Aspire intermediate-optimized IOLs in Europe.”

“This platform has delivered both quality of vision and patient satisfaction since its introduction,” said Luc Bonnefoy, president of surgical at Bausch + Lomb, in the release. “LuxLife is an example of how we plan to build on that success by developing premium options designed to meet the evolving needs of surgeons and patients.”

The LuxLife IOL is available in a range of cylinders spanning from +0.75D to +6.00D, which enables surgeons to treat the 79.5% of patients who have more than 0.5D of corneal astigmatism prior to their cataract surgery. Surgeons are also provided options for injection technique during implantation with LuxLife’s preloaded dual injector system.1

A multicenter, comparative clinical study recently evaluated the LuxLife IOL compared with the monofocal LuxGood IOL and found that patients experienced excellent binocular visual outcomes with LuxLife at near, intermediate, and far distances. The lens also demonstrated high patient satisfaction levels, with 95.6% reporting spectacle independence at intermediate distance and 89.5% at near.1

The IOL is also equipped with 2 unique Allied Ray Technology (ART) Zones, which control and refocus light rays. According to the release, the PRO technology and ART Zones allow the lens to maintain light to the retina.1

"The LuxLife lens provides truly multifocal optical performance, offering an extensive range of clear vision from distance to near,” Francisco Javier Castro Alonso, MD, PhD, of UFR-Miguel Servet University Hospital in Zaragoza, Spain, an investigator in the multicenter clinical study, said in the release. “I consider this lens a first-choice option for patients seeking freedom from glasses at all distances.”

Bausch + Lomb expects LuxLife IOLs to be commercially available in Europe in the coming weeks, with a toric version of the lens to follow. Submissions for regulatory approvals in other countries are ongoing.1

Reference:
  1. Bausch + Lomb receives European CE mark approval for preloaded LuxLife full range of vision intraocular lens. News release. Bausch + Lomb. May 7, 2025. Accessed May 8, 2025. https://www.bausch.com/newsroom/news/?id=260

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karen R. Hoffman, OD, speaks on her AOA 2025 poster, which details a case series on fitting patients with irregular cornea and astigmatism with Zenlens (Bausch + Lomb)
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.